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Summary
Background Patients treated with standard chemotherapy for metastatic or relapsed cervical cancer respond poorly to 
conventional chemotherapy (response achieved in 20–30% of patients) with an overall survival of less than 1 year. High 
tumour angiogenesis and high concentrations of intratumoural VEGF are adverse prognostic features. Cediranib is a 
potent tyrosine kinase inhibitor of VEGFR1, 2, and 3. In this trial, we aimed to assess the eﬀ ect of the addition of 
cediranib to carboplatin and paclitaxel chemotherapy in patients with metastatic or recurrent cervical cancer.
Methods In this randomised, double-blind, placebo-controlled phase 2 trial, which was done in 17 UK cancer 
treatment centres, patients aged 18 years or older initially diagnosed with metastatic carcinoma or who subsequently 
developed metastatic disease or local pelvic recurrence after radical treatment that was not amenable to exenterative 
surgery were recruited. Eligible patients received carboplatin AUC of 5 plus paclitaxel 175 mg/m² by infusion every 
3 weeks for a maximum of six cycles and were randomised centrally (1:1) through a minimisation approach to receive 
cediranib 20 mg or placebo orally once daily until disease progression. The stratiﬁ cation factors were disease site, 
disease-free survival after primary therapy or primary stage IVb disease, number of lines of previous treatment, 
Eastern Cooperative Oncology Group performance status, and investigational site. All patients, investigators, and trial 
personnel were masked to study drug allocation. The primary endpoint was progression-free survival. Eﬃ  cacy 
analysis was by intention to treat, and the safety analysis included all patients who received at least one dose of study 
drug. This trial is registered with the ISCRTN registry, number ISRCTN23516549, and has been completed.
Findings Between Aug 19, 2010, and July 27, 2012, 69 patients were enrolled and randomly assigned to cediranib 
(n=34) or placebo (n=35). After a median follow-up of 24·2 months (IQR 21·9–29·5), progression-free survival was 
longer in the cediranib group (median 8·1 months [80% CI 7·4–8·8]) than in the placebo group (6·7  months 
[6·2–7·2]), with a hazard ratio (HR) of 0·58 (80% CI 0·40–0·85; one-sided p=0·032). Grade 3 or worse adverse 
events that occurred in the concurrent chemotherapy and trial drug period in more than 10% of patients were 
diarrhoea (ﬁ ve [16%] of 32 patients in the cediranib group vs one [3%] of 35 patients in the placebo group), fatigue 
(four [13%] vs two [6%]), leucopenia (ﬁ ve [16%] vs three [9%]), neutropenia (10 [31%] vs four [11%]), and febrile 
neutropenia (ﬁ ve [16%] vs none). The incidence of grade 2–3 hypertension was higher in the cediranib group than in 
the control group (11 [34%] vs four [11%]). Serious adverse events occurred in 18 patients in the placebo group and 
19 patients in the cediranib group.
Interpretation Cediranib has signiﬁ cant eﬃ  cacy when added to carboplatin and paclitaxel in the treatment of 
metastatic or recurrent cervical cancer. This ﬁ nding was accompanied by an increase in toxic eﬀ ects (mainly diarrhoea, 
hypertension, and febrile neutropenia).
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Introduction
Although the incidence of cervical cancer has decreased 
in the UK since 1988,1 it remains the fourth most 
common cancer in women worldwide.2 Radical surgery 
and chemoradiotherapy are associated with high cure 
rates, but treatment options for patients who develop 
metastatic disease or relapse within the irradiated pelvis 
are very unsatisfactory.
A Gynecologic Oncology Group study3 comparing four 
cisplatin-containing doublet combination chemotherapy 
regimens used to treat patients with stage IVb recurrent 
or persistent cervical carcinoma reported typical results 
for patients with advanced cervical cancer. The proportion 
of patients with a response in the four groups of the 
study ranged from 22·3% to 29·1%, and the median 
overall survival was between 9·99 months and 
Lancet Oncol 2015; 16: 1515–24
Published Online
October 14, 2015
http://dx.doi.org/10.1016/
S1470-2045(15)00220-X
See Comment page 1447
Department of Cancer Studies, 
University of Leicester, Leicester, 
UK (Prof R P Symonds FRCR); 
University of Edinburgh Cancer 
Research UK Centre, MRC IGMM, 
Edinburgh, UK 
(Prof C Gourley PhD); The Christie 
NHS Foundation Trust, 
Manchester, UK (S Davidson MD); 
Cancer Research UK Clinical Trials 
Unit, Institute of Cancer 
Sciences, University of Glasgow, 
Glasgow, UK (K Carty, 
E McCartney BSc, D Rai PhD, 
J Paul BSc); Gynaecology Unit, 
Royal Marsden Hospital NHS 
Foundation Trust, London, UK 
(S Banerjee PhD); Institute of 
Oncology, Leeds Cancer Centre, 
St James’s University Hospital, 
Leeds UK (D Jackson PhD); 
Clatterbridge Centre for 
Oncology, University of 
Liverpool, Liverpool, UK 
(R Lord MBChB); Oncology 
Department, University College 
Hospital, London, UK 
(M McCormack FRCR); Velindre 
Hospital, Cardiﬀ , UK 
(E Hudson MBBCh); Beatson 
West of Scotland Cancer Centre, 
Gartnavel General Hospital, 
Glasgow, UK (Prof N Reed MBBS); 
Oncology Department, Poole 
Hospital, Dorset, UK 
(M Flubacher MBBCh); Musgrove 
Park Hospital, Taunton and 
Somerset NHS Foundation 
Trust, Taunton, UK 
(P Jankowska FRCR); 
St Bartholomew’s Hospital, 
London, UK (M Powell MD); and 
Cancer Research UK Manchester 
Institute (Prof C Dive PhD) and 
Institute of Cancer Sciences 
(Prof C M L West PhD), University 
of Manchester, Manchester, UK 
Articles
1516 www.thelancet.com/oncology   Vol 16   November 2015
12·87 months. The most eﬀ ective combination seemed 
to be cisplatin plus paclitaxel, although the diﬀ erence in 
overall survival between the four treatment groups was 
not statistically signiﬁ cant.
High tumour angiogenesis is associated with poor 
survival when cervical cancer is treated with radiotherapy,4 
and high tumour vascularity is a notable prognostic 
factor that is independent of intrinsic tumour 
radiosensitivity.5 Loncaster and colleagues6 reported a 
signiﬁ cant association of VEGF expression in cervical 
cancer biopsies with overall survival (p=0·0008) and 
metastasis-free survival (p=0·0062), but not with local 
control (p=0·23), in a group of 100 patients with bulky 
stage Ib–IIIb tumours treated by radical radiotherapy. 
A review of several tissue marker studies in cervical 
cancer emphasised the importance of increased tumour 
VEGF as an adverse prognostic factor.7 Cediranib is a 
potent inhibitor of the tyrosine kinase activity of VEGFR1, 
2, and 3, and c-KIT. The drug disrupts VEGF signalling 
pathways in endothelial and cancer cells and was 
therefore believed to be a potentially eﬀ ective agent that 
could be added to conventional chemotherapy.8
The rationale for this trial was the notion that no 
satisfactory treatment is available for recurrent or metastatic 
cervical cancer, although platinum-based combinations are 
regarded as the present standard of care. In the selection of 
a chemotherapeutic regimen, toxicity needs to be balanced 
against eﬃ  cacy. Paclitaxel plus carboplatin is a widely used 
treatment for relapsed cervical cancer, partly owing to 
familiarity as a result of its use in ovarian cancer and partly 
because of the assumption that it is likely to have similar 
activity with less toxicity compared with some other 
platinum-based combinations that are used to treat cervical 
cancer. This assumption was supported recently by results 
from the Japan Clinical Oncology Group (JCOG) 0505 
randomised trial9 that showed non-inferiority for paclitaxel 
plus carboplatin versus paclitaxel plus cisplatin. Since 
VEGF concentrations in primary cervical cancer are known 
to aﬀ ect the outcome after radiotherapy, we postulated that 
the addition of the potent VEGFR inhibitor cediranib to 
carboplatin plus paclitaxel would improve progression-free 
survival and response when compared with carboplatin 
plus paclitaxel alone.
Methods
Study design and participants
This phase 2 randomised, double-blind, placebo-
controlled trial included patients with cervical cancer 
who were initially diagnosed with metastatic carcinoma 
or subsequently developed metastatic disease or local 
pelvic recurrence after radical treatment (chemo-
radiotherapy alone or surgery followed by 
chemoradiotherapy).
Eligible patients had metastatic, persistent, or locally 
recurrent cervical cancer that was not amenable to curative 
pelvic exenteration or radical radiotherapy, were at least 
18 years of age, had measurable disease by Response 
Evaluation Criteria in Solid Tumors (RECIST) version 1.1, 
adequate haematological and biochemical function, 
ECOG performance status of 0 or 1, and a life expectancy 
of at least 12 weeks (appendix p 1). The main exclusion 
criteria were previous chemotherapy (except cisplatin 
given concomitantly with radiotherapy as primary 
treatment), previous malignancy within 5 years (except for 
basal cell skin cancer or in-situ breast cancer), pelvic 
ﬁ stulae, evidence of bowel obstruction, major surgery or 
substantial traumatic injury within the previous 4 weeks, 
non-healing wound or bone fracture, active bleeding, pre-
existing thrombotic or haemorrhagic disorder, substantial 
proteinuria, uncontrolled hypertension, or notable allergy 
to carboplatin or paclitaxel.
The study was done in accordance with the 
Declaration of Helsinki and Good Clinical Practice 
guidelines; all aspects of the study received ethics 
approval from the National Research Ethics Service. All 
participants provided written informed consent before 
enrolment. The full study details are available in the 
trial protocol.
Correspondence to:
Prof R Paul Symonds, Emeritus 
Professor of Clinical Oncology, 
c/o Linda Willis, Department of 
Cancer Studies, University of 
Leicester, Osborne Building, 
Leicester Royal Inﬁ rmary, 
Leicester LE1 5WW, UK
rps8@le.ac.uk
For the trial protocol see 
http://www.crukctuglasgow.org/
media/CIRCCa/G121
Research in context
Evidence before this study
We searched PubMed between January, 1990, and January, 
2010, using the terms “cervical cancer”, “chemotherapy”, 
“advanced”, “metastatic”, ”recurrent”, and “trial”. Articles 
published in languages other than English were excluded. From 
phase 3 results, the combination of carboplatin and paclitaxel 
was taken as the standard of care. The addition of “VEGF” to the 
search term found no trials targeting VEGF in cervical cancer 
published before the start of the study.
Added value of this study
The results of our phase 2 study provide evidence that cediranib 
might have therapeutic activity in recurrent or metastatic 
cervical cancer when added to  carboplatin and paclitaxel.
Implicatio ns of all the available evidence
A phase 3 trial reported during the follow-up of patients in this 
trial showed that the addition of bevacizumab to combination 
chemotherapy in patients with advanced cervical cancer 
improved median overall survival. Taken together with the 
results from the CIRCCa study, further study of VEGF inhibition 
is warranted in this disease setting.
See Online for appendix
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Randomisation and masking
Eligible patients were randomly assigned in a 1:1 ratio 
using a minimisation algorithm incorporating a random 
component, stratiﬁ ed by disease site (local relapse only vs 
extra-pelvic metastases only vs local relapse and extra-
pelvic metastases), disease-free survival after primary 
therapy or primary stage IVb disease (≤12 months vs 
>12 months vs treatment-naive stage IVb disease), 
number of lines of previous treatment (0 vs 1); ECOG 
performance status (0 vs 1), and investigational site (the 
centre or institution).
Participants were enrolled by authorised clinicians 
who, after obtaining patient consent, contacted the 
Cancer Research UK Clinical Trials Unit in Glasgow, UK, 
to check eligibility and request randomisation. At the end 
of the randomisation process, the computer 
randomisation system allocated every patient a unique 
identiﬁ cation number and a study drug code that was 
used to access masked local supply of study drug.
All patients, investigators, and trial personnel were 
masked to study drug allocation, with the exception of 
the unmasked statistician who generated and held the 
code break (a masked statistician did the analysis) and 
pharmacovigilance personnel when needed on an 
individual basis for safety reporting to regulatory 
authorities.
Procedures
All patients received carboplatin area under the curve 
(AUC) of 5 (calculated by a radioisotope measurement of 
glomerular ﬁ ltration rate) plus paclitaxel 175 mg/m² 
(infused over 3 h) for up to six cycles repeated every 
3 weeks unless progression or unacceptable toxic eﬀ ects 
supervened. In addition to this treatment, patients were 
randomly assigned 1:1 to receive cediranib 20 mg orally 
or identical placebo orally once daily. Trial medication 
(cediranib or placebo) was continued after the end of 
cytotoxic chemotherapy until tumour progression or the 
development of intolerable toxic eﬀ ects.
Dose modiﬁ cations for haematological toxicity are in 
the appendix (p 2). With the exception of hypertension, 
short dose interruptions of cediranib study tablets were 
the ﬁ rst approach to the management of adverse events, 
followed by dose reduction to 15 mg if necessary. 
Diarrhoea was managed by loperamide (4 mg initially, 
then 2 mg every 2 h), oral or intravenous rehydration, 
and temporary cessation of cediranib medication if 
necessary. In any case of grade 4 thrombocytopenia, the 
cediranib dose was reduced to 15 mg. Hypertension was 
treated with a longacting calcium channel antagonist 
such as nifedipine (initially 5 mg three times per day, 
increasing to 20 mg three times per day depending on 
response), with temporary cessation of cediranib if 
necessary. The scheme for management of hypertension 
is shown in the appendix (p 3).
Patients were assessed for toxicity, haematology, clinical 
chemistry, vital signs, blood pressure, and urinalysis at the 
beginning of each cycle of chemotherapy and subsequently 
at clinic visits every 2 months. Thyroid function was tested 
every 2 months during follow-up. Patients were assessed 
for response clinically and radiologically after two, four, 
and six cycles of chemotherapy. Subsequently, CT or MRI 
scans (only one modality was used per patient) were done 
every 2 months until conﬁ rmed tumour progression 
according to RECIST version 1.1. When disease 
progression was conﬁ rmed, further treatment was given 
at the investigator’s discretion. Blood was taken for 
plasma-soluble VEGFR2 (sVEGFR2) before treatment, at 
the beginning of every cycle of chemotherapy, and every 
2 months after chemotherapy.
Quality of life was assessed with the European 
Organisation for Research and Treatment of Cancer 
(EORTC) QLQ-C30 and QLQ-CX24 questionnaires, 
which were given to patients at the onset of every cycle of 
chemotherapy, at the end of treatment, and every 
2 months during the ﬁ rst year of follow-up or until 
conﬁ rmed progression.
Outcomes
The primary endpoint was progression-free survival, 
deﬁ ned as time from randomisation to progression or 
death (whichever occurred ﬁ rst). Secondary endpoints 
were a reduction in sVEGFR2 concentration from 
baseline to day 28 after initiation of chemotherapy, best 
response to chemotherapy (according to RECIST 
version 1.1 criteria), overall survival (deﬁ ned as time from 
randomisation to death from any cause), toxic eﬀ ects 
(assessed with National Cancer Institute Common 
Terminology Criteria for Adverse Events, version 4.0), 
and quality of life as assessed by EORTC QLQ-C30 and 
QLQ-CX24.
Progression and response were assessed locally by 
investigators, but the scan outcomes were detailed in the 
study case report form and subsequently checked 
centrally against RECIST criteria as part of the process of 
data cleaning before analysis.
Statistical analysis
We calculated that we needed a sample size of 80 patients 
(40 per group) to record 69 progression events or deaths. 
The study was designed based on the methods of 
Rubinstein and colleagues10 to detect a 50% improvement 
in median progression-free survival with cediranib from 
4 months to 6 months with 80% power, at a 20% one-
sided level of signiﬁ cance (corresponding to a hazard 
ratio [HR] of 0·667). This sample size also provided 85% 
power at the 10% one-sided level of signiﬁ cance to detect 
a 75% increase in median progression-free survival from 
4 months to 7 months (HR 0·571).
A result favouring cediranib that was signiﬁ cant at the 
one-sided 10% level would suggest that a subsequent 
phase 3 trial should be done. A result favouring 
cediranib that was signiﬁ cant at the one-sided 20% level 
but not at the one-sided 10% level would mean that 
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other supportive data are needed—ie, a signiﬁ cant 
diﬀ erence in plasma sVEGFR2 concentration from 
baseline to day 28 between groups (a greater reduction 
in the cediranib group) before a subsequent phase 3 
trial could be considered. A result that was not 
signiﬁ cant at the 20% level would suggest that no 
further development of cediranib should be done in this 
setting. This method of decision-making conforms to a 
three-outcome approach.11
Data from Batchelor and colleagues’ study12 showed 
that the standard deviation in the change in sVEGFR2 
(log 10) concentration from baseline was 0·19 and the 
expected change was 0·27. Under the assumption of no 
change in the placebo group, to detect this diﬀ erence 
between the groups would need 54 patients (90% power, 
10% one-sided level of signiﬁ cance). Allowing for 10% of 
patients being non-assessable (ie, 10% would have 
disease progression or die before day 28), our study 
aimed to recruit 60 patients in whom this pharma-
codynamic endpoint could be measured.
Eﬃ  cacy analysis of progression-free and overall 
survival included all randomly assigned patients 
(intention-to-treat population). Analysis of response was 
restricted to those patients who, on data review, had 
measurable disease at baseline. Analysis of treatment 
delivery, quality of life, and safety was restricted to those 
patients who started study treatment and were analysed 
by original randomised group.
We estimated progression-free and overall survival using 
the Kaplan-Meier method. We used a Cox proportional 
hazards model incorporating study stratiﬁ cation factors to 
compare the study groups. We used logistic regression to 
compare overall response (complete or partial response) 
via the odds ratio between the study groups in a model 
incorporating study stratiﬁ cation factors. A 10% one-sided 
level of statistical signiﬁ cance was used for this.
We did an exploratory analysis of treatment eﬀ ect 
heterogeneity for progression-free and overall survival by 
key patient or disease factors (stratiﬁ cation factors, age, 
and histology). The p value for heterogeneity was derived 
by comparing the likelihood ratios of two stratiﬁ ed Cox 
models: a full model with a term for treatment eﬀ ect in 
each key factor category and a reduced model with one 
term for treatment eﬀ ect.
We compared the change in sVEGFR2 (log 10) values 
from baseline to day 28 between the study groups using a 
t test. In the cediranib group, the association between 
this change and progression-free survival and response 
was assessed in the context of Cox and logistic regression 
models, respectively.
For the quality-of-life analysis, we imputed missing data 
using interpolation and last observation carried forward 
before deriving the AUC described by each scale. 
We standardised these AUC values by the time spent in the 
study and adjusted them by subtracting the baseline value. 
We compared the distributions of the adjusted standardised 
AUC scores between the groups with the Mann-Whitney 
U test. We adjusted the p values for the individual tests 
within each questionnaire for multiple comparisons using 
the false-discovery rate approach (calculated using the p.
adjust function [ fdr option] of the stats library in R version 
3.1.2). With the assumption of a standard deviation of 2313 
the study has 90% power to detect a large diﬀ erence of 2014 
at the 1% two-sided level of signiﬁ cance (to allow for 
multiple testing). A 5% level of signiﬁ cance was used for 
the quality-of-life comparisons. All p values in the text are 
two-sided unless stated otherwise.
SPSS version 22.0 was used for all analyses. The 
statistical analysis plan for the study was produced and 
approved before the ﬁ rst Data Monitoring Committee 
meeting. This study is registered as an International 
Standard Randomised Controlled Trial, number 
ISRCTN23516549.
Figure 1: Trial proﬁ le
*One patient in this group was given chemotherapy but did not receive any trial drug. †Two patients withdrew 
from the study before starting treatment and are censored for progression-free and overall survival at this point.
91 patients screened
69 patients randomly assigned
35 randomly allocated to placebo
 35 received chemotherapy or trial drug*
34 randomly allocated to cediranib
 32 received chemotherapy or trial drug
  2 did not receive chemotherapy or trial drug
   1 withdrew consent
   1 ineligible and taken oﬀ study (pulmonary 
embolism)
0 continuing to take trial drug
 34 discontinued trial drug
1 death
19 progressions 
1 diarrhoea
6 other toxicity related to treatment
7 not related to treatment
1 continuing to take trial drug
 31 discontinued trial drug
4 deaths
16 progressions 
1 patient refusal
1 diarrhoea
3 other toxicity related to treatment
5 not related to treatment
1 withdrew consent
Follow-up status for 35 patients in intention-to-
treat population:
 0 no post-baseline data
29 achieved eﬃcacy endpoint
 2 continuing in follow-up
 2 lost to follow-up
 2 withdrew consent
Follow-up status for 34 patients in intention-to- 
treat population:
 2 no post-baseline data
26 achieved eﬃcacy endpoint
 4 continuing in follow-up
 0 lost to follow-up
 2 withdrew consent
35 included in progression-free survival/overall
 survival analysis
 31 included in response analysis
  4 excluded from analysis (no baseline target 
lesions)
 35 included in safety analysis
34 included in progression-free survival and overall
 survival analysis†
 33 included in response analysis
  1 excluded from analysis (no baseline target 
lesions)
 32 included in safety analysis
22 patients did not enter study
 16 ineligible
  6 declined
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Role of the funding source
The funders had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
All authors had full access to all the raw data. The 
corresponding author had full access to all the data in the 
study and had ﬁ nal responsibility for the decision to 
submit for publication.
Results
Between Aug 19, 2010, and July 27, 2012, 91 patients were 
screened and 69 eligible patients were enrolled from 
17 cancer centres in the UK (appendix p 4). Five patients 
(four assigned to placebo and one assigned to cediranib) 
were excluded from the analysis of response because 
they had no measurable disease at baseline. Two patients 
(both in the cediranib group) were excluded from the 
safety analysis because they did not start chemotherapy 
or receive any study drug. Figure 1 shows the patient 
ﬂ ow through the trial. Table 1 shows the baseline patient 
characteristics by treatment group.
The trial closed prematurely on July 27, 2012, owing to 
withdrawal of drug supply. Median follow-up was 
24·2 months (IQR 21·9–29·5).
The administration of paclitaxel and carboplatin was 
similar between the treatment groups. The median total 
carboplatin dose delivered was an AUC of 30 (IQR 15–30) 
in the placebo group and AUC of 29 (25–30) in the 
cediranib group. The number of patients completing 
the full six cycles of paclitaxel and carboplatin treatment 
was 24 (69%) of 35 patients in the placebo group and 
26 (81%) of 32 patients in the cediranib group. Seven 
(20%) of 35 patients in the placebo group and 11 (34%) 
of 32 in the cediranib group had one or more dose 
reduction. 23 (66%) patients in the placebo group and 
19 (59%) patients in the cediranib group had one or 
more dose delay. The median total paclitaxel dose 
delivered was 1013 mg/m² (IQR 699–1050) in the 
placebo group and 1033 mg/m² (861–1051) in the 
cediranib group. The number of patients completing 
the full six cycles of treatment was 22 (63%) in the 
placebo group and 25 (78%) in the cediranib group. 
12 (34%) patients in the placebo group had one or more 
dose reduction and 24 (69%) had one or more dose 
delays, compared with 14 (44%) and 20 (63%), 
respectively, in the cediranib group.
The median time on study drug was 4·4 months 
(IQR 1·6–5·3) in the placebo group and 4·4 months 
(2·5–6·7) in the cediranib group. Compliance with the 
study drug was good in both groups; the median 
Placebo (n=35) Cediranib (n=34)
Age (years) 44 (34–53) 44 (37–60)
ECOG performance status at 
randomisation
0 14 (40%) 17 (50%)
1 21 (60%) 17 (50%)
Treatment-naive stage IVb disease 3 (9%) 3 (9%)
Disease site
Local relapse only 3 (9%) 6 (18%)
Extra-pelvic metastases only 12 (34%) 9 (26%)
Local relapse and extra-pelvic 
metastases
20 (57%) 19 (56%)
Time from ﬁ rst pathological 
diagnosis to relapse, weeks*
61 (32–129) 59 (35–145)
Disease-free survival after primary 
therapy/primary stage IVb
≤12 months 16 (46%) 14 (41%)
>12 months 16 (46%) 17 (50%)
Stage IVb 3 (9%) 3 (9%)
Histology†
Squamous 26 (74%) 21 (64%)
Adenocarcinoma 7 (20%) 7 (21%)
Mixed 1 (3%) 4 (12%)
Other 1 (3%) 1 (3%)
Degree of diﬀ erentiation†
Well 5 (14%) 1 (3%)
Moderate 12 (34%) 13 (39%)
Poor 11 (31%) 13 (39%)
Unknown 7 (20%) 6 (18%)
Previous treatment†
Previous radiotherapy 32 (91%) 30 (91%)
Previous chemotherapy 
(cisplatin with radiotherapy)
29 (83%) 27 (82%)
Previous surgery 19 (54%) 18 (55%)
Data are median (IQR) or n (%). *For this row, n=25 in placebo group and n=28 in 
cediranib group. †Data available for 33 patients in the cediranib group.
Table 1: Baseline characteristics Figure 2: Progression-free survival
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percentage of doses missed was 3% (IQR 0–8) in the 
placebo group and 7% (1–18) in the cediranib group. 
Disease progression or death was the most common 
reason for treatment discontinuation in both groups 
(19 [54%] of 35 patients in the placebo group vs 20 [63%] of 
32 patients in the cediranib group). Seven (20%) of 
35 patients in the placebo group and four (13%) of 32 in 
the cediranib group discontinued treatment because of 
adverse events.
All eﬃ  cacy analyses of progression-free and overall 
survival were done on the intention-to-treat population. 
Two patients in this population (both in the cediranib 
group) withdrew before starting study treatment, and 
therefore had no survival, trial drug, or chemotherapy 
data available. These patients were both censored for 
progression-free and overall survival before any events 
on study and therefore their data made no contribution 
to the comparison of the study groups, although they are 
included in the Kaplan-Meier plots.
55 progression-free survival events were recorded, 
which means that by post-hoc calculations, the study has 
roughly 80% power at the 20% one-sided level of 
signiﬁ cance to detect a 60% increase in progression-free 
survival, or 80% power at the 10% one-sided signiﬁ cance 
level to detect a 75% increase in median progression-free 
survival (hazard ratio [HR] 0·625 or 0·571, respectively). 
The median progression-free survival of patients 
receiving cediranib was 8·1 months (80% CI 7·4–8·8) 
compared with 6·7 months (6·2–7·2) for those in the 
placebo group. The HR for cediranib versus placebo, 
adjusted for stratiﬁ cation factors, was 0·58 (80% CI 
0·40–0·85, one-sided p=0·032; ﬁ gure 2). An exploratory 
examination of heterogeneity in progression-free survival 
by stratiﬁ cation factors, age, and histology (appendix p 7) 
suggested that the eﬀ ect of cediranib on progression-free 
survival might depend on length of disease-free survival 
after primary therapy (p=0·047) and disease site (p=0·062) 
but not age, histological subtype, number of previous 
treatments, or performance score at randomisation.
27 patients died in the placebo group and 25 died in the 
cediranib group. Median overall survival did not diﬀ er 
signiﬁ cantly between the two treatment groups (ﬁ gure 3). 
An exploratory examination of heterogeneity suggested 
that the eﬀ ect of cediranib on overall survival might 
depend on disease site (test of treatment eﬀ ect 
heterogeneity p=0·034; patients with extra-pelvic 
metastatic disease only derive a greater beneﬁ t compared 
to those with local relapse (with or with metastatic 
disease), but not on age, histological subtype, length of 
disease free survival, number of previous treatments, or 
performance status score at randomisation (apppendix p 8).
The proportion of patients with an overall response in 
the cediranib group was 64% (three [9%] of 33 patients 
had a complete response and 18 [55%] had a partial 
response) compared with 45% in the placebo group 
(none of 31 patients had a complete response and 14 [45%] 
had a partial response). The odds ratio from logistic 
regression when adjusted for stratiﬁ cation factors for 
cediranib versus placebo was 2·23 (80% CI 1·06–4·69; 
10% one-sided p=0·084).
Figure 3: Overall survival
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Global health status as assessed by the EORTC QLQ-C30 
questionnaire is shown in ﬁ gure 4 (details of questionnaire 
completion are in appendix p 5). AUC analysis of the data 
over the whole study period showed no signiﬁ cant 
diﬀ erence for this scale.  The median standardised 
adjusted AUC  was –5·4 (95% CI –13·1 to –1·0) in the 
placebo group and –11·1 (–20·8 to –7·4)  in the cediranib 
group (p=0·50, after adjustment for multiple comparisons). 
There was a signiﬁ cantly worse quality of life associated 
with diarrhoea in the cediranib group (median diﬀ erence 
in standardised adjusted AUC 18 [95% CI 5–37], p=0·030, 
after adjustment for multiple comparisons). No other 
scales derived from the EORTC QLQ-C30 or EORTC QLQ-
CX24 questionnaires had signiﬁ cant diﬀ erences between 
the study groups (appendix p 5).
Table 2 shows the laboratory and non-laboratory 
adverse events that occurred in at least 10% of patients in 
either group during the chemotherapy and study drug 
period. Grade 3 or worse adverse events that occurred in 
more than 10% of patients were diarrhoea (ﬁ ve [16%] of 
32 patients in the cediranib group vs one [3%] of 
35 patients in the placebo group), fatigue (four [13%] vs 
two [6%]), leucopenia (ﬁ ve [16%] vs three [9%]), 
neutropenia (10 [31%] vs four [11%]), and febrile 
neutropenia (ﬁ ve [16%] vs none [0%]). Serious adverse 
events occurred in 18 patients in the placebo group 
(30 events) and 19 patients in the cediranib group 
(41 events). The remaining grade 3 or greater laboratory 
and non-laboratory adverse events (those associated with 
events occurring in <10% of patients) are listed in 
appendix p 6. Although there was no diﬀ erence in 
grade 3 or 4 hypertension between the treatment groups, 
grade 1–2 hypertension occurred in 19 (59%) of patients 
in the cediranib group and eight (23%) of patients in the 
placebo group. The incidence of grade 2 hypertension 
was higher in the cediranib group (11 [34%] of 32 patients) 
than in the placebo group (three [9%] of 35 patients). No 
cases of grade 4 hypertension occurred. Five patients in 
the cediranib group reported a total of ﬁ ve occurrences of 
febrile neutropenia (two grade 4 and three grade 3); all 
were recorded as being unrelated to the study drug. 
During the trial drug only maintenance period, toxic 
eﬀ ects were infrequent (appendix p 6). One patient died 
of a colon perforation after one cycle of carboplatin, 
paclitaxel, and cediranib. The role of cediranib in this 
death is uncertain. The tumour was adjacent to the colon 
before the start of therapy.
61 (88%) of 69 patients gave consent for blood samples 
to be taken for sVEGFR2 marker analysis. Mean 
sVEGFR2 concentration increased in the placebo group 
and decreased in the cediranib group from baseline to 
day 28 (cycle 2, day 8; ﬁ gure 5). The point estimate for the 
diﬀ erence (cediranib–placebo) between the treatment 
groups in change in sVEGFR2 (log 10) from baseline to 
day 28 (cycle 2, day 8) was –0·108 (80% CI –0·147 to 
–0·070; 10% one-sided p=0·00077). This estimate is based 
on 22 patients in the placebo group and 18 patients in the 
Placebo (n=35) Cediranib (n=32)
Grade 1–2 Grade 3 Grade 4 Grade 1–2 Grade 3 Grade 4
Non-laboratory adverse events*
Abdominal pain 2 (6%) 1 (3%) 0 (0%) 4 (13%) 0 (0%) 0 (0%)
Alopecia 20 (57%) 1 (3%) 0 (0%) 17 (53%) 0 (0%) 0 (0%)
Anaemia 6 (17%) 3 (9%) 0 (0%) 3 (9%) 1 (3%) 1 (3%)
Anorexia 4 (11%) 0 (0%) 0 (0%) 7 (22%) 1 (3%) 0 (0%)
Arthralgia 4 (11%) 0 (0%) 0 (0%) 3 (9%) 1 (3%) 0 (0%)
Constipation 21 (60%) 0 (0%) 0 (0%) 16 (50%) 2 (6%) 0 (0%)
Diarrhoea 14 (40%) 1 (3%) 0 (0%) 24 (75%) 5 (16%) 0 (0%)
Dysgeusia 0 (0%) 0 (0%) 0 (0%) 3 (9%) 0 (0%) 0 (0%)
Dyspnoea 0 (0%) 0 (0%) 0 (0%) 4 (13%) 0 (0%) 0 (0%)
Fatigue 27 (77%) 2 (6%) 0 (0%) 26 (81%) 4 (13%) 0 (0%)
Febrile neutropenia 0 (0%) 0 (0%) 0 (0%) 0 (0%) 3 (9%) 2 (6%)
Headache 0 (0%) 0 (0%) 0 (0%) 5 (16%) 0 (0%) 0 (0%)
Hypertension 8 (23%) 1 (3%) 0 (0%) 19 (59%) 0 (0%) 0 (0%)
Infections and infestations 3 (9%) 0 (0%) 0 (0%) 1 (3%) 1 (3%) 0 (0%)
Limb oedema 3 (9%) 0 (0%) 0 (0%) 2 (6%) 0 (0%) 0 (0%)
Maculopapular rash 3 (9%) 0 (0%) 0 (0%) 2 (6%) 0 (0%) 0 (0%)
Myalgia 8 (23%) 0 (0%) 0 (0%) 6 (19%) 0 (0%) 0 (0%)
Nausea 22 (63%) 1 (3%) 0 (0%) 20 (63%) 1 (3%) 0 (0%)
Oral mucositis 8 (23%) 0 (0%) 0 (0%) 11 (34%) 1 (3%) 0 (0%)
Pain 3 (9%) 0 (0%) 0 (0%) 5 (16%) 1 (3%) 0 (0%)
Paresthesia 4 (11%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Peripheral motor 
neuropathy
3 (9%) 0 (0%) 0 (0%) 6 (19%) 0 (0%) 0 (0%)
Peripheral sensory 
neuropathy
16 (46%) 0 (0%) 0 (0%) 16 (50%) 2 (6%) 0 (0%)
Proteinuria 8 (23%) 0 (0%) 0 (0%) 7 (22%) 2 (6%) 0 (0%)
Urinary tract infection 2 (6%) 1 (3%) 0 (0%) 2 (6%) 0 (0%) 0 (0%)
Vomiting 12 (34%) 2 (6%) 0 (0%) 11 (34%) 2 (6%) 0 (0%)
Haematology
Anaemia 34 (97%) 1 (3%) 0 (0%) 28 (88%) 2 (6%) 1 (3%)
Neutropenia 15 (43%) 3 (9%) 1 (3%) 13 (41%) 9 (28%) 1 (3%)
Thrombocytopenia 3 (9%) 0 (0%) 1 (3%) 5 (16%) 0 (0%) 0 (0%)
Leucopenia 25 (71%) 3 (9%) 0 (0%) 22 (69%) 5 (16%) 0 (0%)
Biochemistry
Albumin (low) 8 (23%) 2 (6%) 0 (0%) 7 (22%) 0 (0%) 0 (0%)
Alkaline phosphatase (high) 15 (43%) 0 (0%) 0 (0%) 15 (47%) 0 (0%) 0 (0%)
Alanine transaminase (high) 6 (17%) 0 (0%) 0 (0%) 12 (38%) 1 (3%) 0 (0%)
Aspartate transaminase 
(high)
2 (6%) 0 (0%) 0 (0%) 9 (28%) 0 (0%) 0 (0%)
Bilirubin (high) 1 (3%) 0 (0%) 0 (0%) 3 (9%) 2 (6%) 0 (0%)
Calcium (high) 3 (9%) 0 (0%) 0 (0%) 2 (6%) 0 (0%) 1 (3%)
Calcium (low) 3 (9%) 0 (0%) 0 (0%) 4 (13%) 1 (3%) 0 (0%)
Creatinine (high) 8 (23%) 0 (0%) 0 (0%) 6 (19%) 0 (0%) 0 (0%)
Glucose (high) 9 (26%) 0 (0%) 0 (0%) 15 (47%) 0 (0%) 0 (0%)
Potassium (high) 3 (9%) 0 (0%) 0 (0%) 5 (16%) 0 (0%) 1 (3%)
Potassium (low) 3 (9%) 1 (3%) 0 (0%) 6 (19%) 2 (6%) 0 (0%)
Sodium (low) 8 (23%) 2 (6%) 0 (0%) 12 (38%) 2 (6%) 0 (0%)
Data are n (%). *Association with either chemotherapy or study drug must be at least “possible”. There was one possible 
treatment-related death in the cediranib group.
Table 2: Laboratory and non-laboratory adverse events occurring in at least 10% of patients in either group 
during chemotherapy and study drug period
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cediranib group for whom data were available at both 
time points. Analyses showed no evidence for an 
association between the change in sVEGFR2 (log 10) 
concentration from baseline to day 28 and either 
progression-free survival (p=0·90, n=18) or response 
(p=0·22, n=17) in the cediranib group.
Discussion
This randomised, placebo-controlled, phase 2 trial shows 
that the addition of cediranib to carboplatin and paclitaxel 
chemotherapy resulted in longer progression-free 
survival and a greater proportion of patients achieving an 
overall response than did carboplatin and paclitaxel alone 
in patients with metastatic or recurrent cervical cancer.
Although cross-trial comparisons should be interpreted 
with caution, the response and progression-free survival 
results in the control (placebo) group of our study were 
similar to other published series; indeed, the progression-
free survival in our study was longer than that reported in 
other series. Lorusso and colleagues15 did a systematic 
review of the published literature comparing cisplatin and 
carboplatin plus paclitaxel-based chemotherapy for 
recurrent or metastatic cervical cancer, for which they 
included 17 eligible studies. The proportion of patients with 
an objective response for the carboplatin-based combination 
was 48·5%, with a median progression-free survival of 
5 months compared with 45% of patients achieving a 
response and a progression-free survival of 6·7 months in 
this study. Survival in the control group exceeded our 
expectation based on our previous experience in a phase 2 
trial of docetaxel and gemcitabine.16 However, our study 
might have enrolled a group of patients who had a better 
than expected prognosis. In comparison with JCOG0505,9 
fewer patients were enrolled who presented with local 
relapse only (13% in our study vs 38% in JCOG0505). 
Similarly, in our study, a disease-free survival after primary 
therapy of longer than 12 months occurred in 48% of 
patients  (compared with 23% in JCOG0505), which is a 
good prognostic feature. Although patients in our trial 
might have had a better prognosis than those reported in 
other studies, it should be noted that the two treatment 
groups were well balanced for prognostic factors.
The increase in response and progression-free survival 
in the cediranib group was achieved with an increase in 
neutropenia, febrile neutropenia, diarrhoea, and 
hypertension. The increase in neutropenia was associated 
with a small but signiﬁ cant increase in neutropenic sepsis.
Overall survival did not diﬀ er between the two groups 
but, since the study was curtailed prematurely owing to 
problems with drug supply at a recruitment of 69 patients, 
and the trial was powered for the primary endpoint of 
progression-free survival, the trial was not adequately 
powered to show a diﬀ erence in overall survival. 
However, there are a small number of long-term 
survivors in both the cediranib and placebo groups 
(ﬁ gure 2) with seven patients in each group alive at 
24 months.
Although exploratory tests for treatment heterogeneity 
suggested that the eﬀ ect of cediranib might be stronger 
in patients with metastatic disease (for both overall and 
progression-free survival) and with a disease-free interval 
longer than 12 months (for progression-free survival), 
these observations should be treated with caution in view 
of the modest levels of signiﬁ cance recorded (even before 
consideration of adjustments for multiple testing) and 
the small number of patients in each category.
Overall, our data show that mean plasma sVEGFR2 
concentration decreased from baseline after the ﬁ rst cycle 
of chemotherapy in the cediranib group and increased in 
the placebo group. There was a signiﬁ cant diﬀ erence in 
the change in sVEGFR2 concentration from baseline to 
28 days between the two groups. Our study is the ﬁ rst trial 
to investigate the eﬃ  cacy of cediranib in cervical cancer 
and this secondary endpoint was chosen to provide proof-
of-principle for cediranib inhibition of VEGF signalling in 
the disease. In a phase 1 trial of cediranib in advanced solid 
tumours, time-dependent and dose-dependent reductions 
in sVEGFR2 concentrations were recorded.17 A dose of 
20 mg led to a roughly 22% reduction from baseline in 
sVEGFR2 concentration at day 28. In a phase 1 trial of 
cediranib in acute myeloid leukaemia, Fiedler and 
colleagues18 also reported time-dependent reductions in 
Figure 5: Mean sVEGFR2 concentration (log 10) by timepoint
Error bars are standard errors. sVEGFR2=plasma-soluble VEGFR2. *Two baseline measurements were taken for each 
patient (these are replicate results).
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plasma sVEGFR2 levels. Batchelor and co-workers19 
reported an average 36% reduction from baseline at day 28 
in sVEGFR2 concentration in 16 patients with glioblastoma 
treated with a 45 mg dose of cediranib. The reductions in 
sVEGFR2 concentration recorded in our trial are consistent 
with the ﬁ ndings from other cancers and support its use as 
a biomarker of the biological activity of cediranib. Although 
we found no evidence for an association between a 
decrease in sVEGFR2 and tumour response or progression-
free survival in the cediranib group, the number of 
evaluable patients was small.
Before we began our study, a Gynecologic Oncology 
Group (GOG) phase 2 study20 (GOG 227c) showed partial 
responses to bevacizumab monotherapy in 11% of 
patients with metastatic cervical cancer with a median 
response time of 6·21 months (range 2·83–8·28); all 
patients received bevacizumab as second-line or third-
line treatment. Since the end of recruitment to our study, 
GOG has shown the beneﬁ t of adding bevacizumab to 
either cisplatin and paclitaxel or topotecan and paclitaxel 
given as the initial treatment for recurrent or metastatic 
cervical cancer. The addition of bevacizumab to 
chemotherapy compared with chemotherapy alone 
increased the response to chemotherapy (48% vs 36%, 
p=0·008), progression-free survival (8·2 months vs 
5·9 months, HR 0·68 [95% CI 0·54–0·82]), and overall 
survival (17·0 months vs 13·3 months, HR 0·68 
[98% CI 0·54–0·95).21
The GOG study using a monoclonal antibody to VEGF 
and our trial of a VEGFR tyrosine kinase inhibitor shows 
the value of targeting angiogenesis in combination with 
chemotherapy in the management of metastatic or 
relapsed cervical cancer. Since VEGF expression is an 
important factor aﬀ ecting the outcome of patients treated 
with radiotherapy, combinations of anti-angiogenic 
agents and radiotherapy could be of value in locally 
advanced disease. Although side-eﬀ ects such as diarrhoea 
might be increased, our experience is that diarrhoea 
caused by cediranib can be controlled through the use of 
drugs such as loperamide. No deterioration in overall 
quality of life occurred, which was also the case in the 
GOG 240 phase 3 trial of bevacizumab.22 Both studies 
suggest that patients who progress following anti-
angiogenesis therapy might be suitable for investigation 
of novel second-line treatments. In view of the impressive 
overall survival advantage shown in GOG 240, the value 
of a direct comparison between bevacizumab and 
cediranib is debatable, but the evidence that both agents 
are eﬀ ective opens up the potential for studies of multi-
anti-angiogenic combinations, sequencing of anti-
angiogenics, or trials of anti-angiogenics and biological 
agents with pre-existing evidence of synergy, including 
poly-ADP ribose polymerase inhibitors.23
Phase 3 trials have shown no beneﬁ t of the addition of 
cediranib to paclitaxel and carboplatin in lung cancer,24 to 
standard combination chemotherapy in colorectal cancer,25,26 
or to lomustine in glioblastoma.19 The absence of clinically 
meaningful eﬃ  cacy in lung and colorectal cancer led 
AstraZeneca to stop its sponsored development of the drug 
in 2011, which led to the drug supply problems in our 
study.27 Since then, an investigator-led phase 3 trial28 in 
women with recurrent ovarian cancer showed that cediranib 
given concurrently with platinum-based chemotherapy 
improved progression-free survival and, when continued as 
maintenance therapy, signiﬁ cantly improved both 
progression-free and overall survival. More recently, a 
phase 2 trial23 showed that the combination of cediranib 
with olaparib nearly doubled progression-free survival 
compared with olaparib alone in women with platinum-
sensitive recurrent ovarian cancer. As a result, the present 
focus of cediranib development in gynaecological cancers is 
in combination with a PARP inhibitor in patients with 
either platinum-sensitive or platinum-resistant ovarian 
cancer. Our ﬁ nding supports the ongoing assessment 
cediranib in patients with cervical cancer.
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